United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about the broad US market.
Directly affected
- UTHR United Therapeutics+27.5% 30d
Named in this report.
Indirectly affected
- DIA SPDR Dow Jones Industrial Average ETF+0.1% 30d
SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- QQQ Invesco QQQ-9.8% 30d
Invesco QQQ: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story.
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that United Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+22.4% 30d
Eli Lilly and is a peer of United Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson-1.7% 30d
Johnson & Johnson is a peer of United Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+7.8% 30d
AbbVie is a peer of United Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+1.9% 18d
Merck is a peer of United Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+6.9% 30d
Abbott Laboratories is a peer of United Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| UTHR | -2.53% | -0.47% | base | after close | after close | after close | after close |
| DIA | +1.47% | -0.00% | base | after close | after close | after close | after close |
| QQQ | +5.88% | +0.76% | base | after close | after close | after close | after close |
| XLV | -2.31% | +0.48% | base | after close | after close | after close | after close |
| LLY | -8.42% | +0.54% | base | after close | after close | after close | after close |
| JNJ | +1.93% | +2.66% | base | after close | after close | after close | after close |
| ABBV | +0.13% | +3.12% | base | after close | after close | after close | after close |
| MRK | -2.47% | +3.37% | base | after close | after close | after close | after close |
| ABT | -6.15% | -2.89% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings ChartMill
Source: ChartMill
How far Spdr Dow Jones Industrial Average Etf Trust (DIA) has moved since 4 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | +3.12% | final price |
| ABBV | five days earlier | +0.13% | final price |
| ABT | three days earlier | -2.89% | final price |
| ABT | five days earlier | -6.15% | final price |
| Spdr Dow Jones Industrial Average Etf Trust (DIA) | three days earlier | -0.00% | final price |
| Spdr Dow Jones Industrial Average Etf Trust (DIA) | five days earlier | +1.47% | final price |
| JNJ | three days earlier | +2.66% | final price |
| JNJ | five days earlier | +1.93% | final price |
| LLY | three days earlier | +0.54% | final price |
| LLY | five days earlier | -8.42% | final price |
| MRK | three days earlier | +3.37% | final price |
| MRK | five days earlier | -2.47% | final price |
| Invesco Qqq Trust, Series 1 (QQQ) | three days earlier | +0.76% | final price |
| Invesco Qqq Trust, Series 1 (QQQ) | five days earlier | +5.88% | final price |
| UTHR | three days earlier | -0.47% | final price |
| UTHR | five days earlier | -2.53% | final price |
| XLV | three days earlier | +0.48% | final price |
| XLV | five days earlier | -2.31% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 35 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 57 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 51 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 61 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 77 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 33 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 47 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Spdr Dow Jones Industrial Average Etf Trust (DIA)
Companies mentioned with this story
- DIA Spdr Dow Jones Industrial Average Etf Trust
For “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings,” Spdr Dow Jones Industrial Average Etf Trust (DIA) is linked, with no stored direction, medium confidence. Reason on file: SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
- QQQ Invesco Qqq Trust, Series 1
In “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings,” Invesco Qqq Trust, Series 1 (QQQ) is linked, with no stored direction, medium confidence. Reason on file: Invesco QQQ: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
- IWM Ishares Tr
Ishares Tr (IWM) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings.” Reason on file: iShares Russell 2000 ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
- RSP Invesco Exchange Traded Fd T
For “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings,” Invesco Exchange Traded Fd T (RSP) is linked, with no stored direction, medium confidence. Reason on file: Invesco S&P 500 Equal Weight ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
- VTI Vanguard Index Fds
Vanguard Index Fds (VTI) is linked, with no stored direction, medium confidence in the 4 Nov 2026 story “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings.” Reason on file: Vanguard Total Stock Market ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
Spdr Dow Jones Industrial Average Etf Trust (DIA)
On 4 Nov 2026, “United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings” is the story that connects Spdr Dow Jones Industrial Average Etf Trust (DIA) to this story.
The link for Spdr Dow Jones Industrial Average Etf Trust (DIA) is this: SPDR Dow Jones Industrial Average ETF: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
Invesco Qqq Trust, Series 1 (QQQ) is here too. Its reason reads: Invesco QQQ: it is a broad US stock-market fund. Linked by “nasdaq” (the broad US market) in this story
Dates and price levels for Spdr Dow Jones Industrial Average Etf Trust (DIA)
DIA traded between 504.92 and 522.62 across 18 sessions. The latest close on file is 515.65. IWM traded between 269.88 and 285.25 across 20 sessions. The latest close on file is 279.20. QQQ traded between 680.34 and 757.18 across 20 sessions. The latest close on file is 685.32.
A simple score for Spdr Dow Jones Industrial Average Etf Trust (DIA)
40 out of 100
“United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings” scores 40 out of 100. The score uses 1 sources, and 5 linked companies.